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Abstract
Background: Despite the availability of effective therapies, asthma remains a source of significant morbidity and
use of health care resources. The central research question of the ACCURATE trial is whether maximal doses of
(combination) therapy should be used for long periods in an attempt to achieve complete control of all features of
asthma. An additional question is whether patients and society value the potential incremental benefit, if any,
sufficiently to concur with such a treatment approach. We assessed patient preferences and cost-effectiveness of
three treatment strategies aimed at achieving different levels of clinical control:
1. sufficiently controlled asthma
2. strictly controlled asthma
3. strictly controlled asthma based on exhaled nitric oxide as an additional disease marker
Design: 720 Patients with mild to moderate persistent asthma from general practices with a practice nurse, age
18-50 yr, daily treatment with inhaled corticosteroids (more then 3 months usage of inhaled corticosteroids in the
previous year), will be identified via patient registries of general practices in the Leiden, Nijmegen, and Amsterdam
areas in The Netherlands. The design is a 12-month cluster-randomised parallel trial with 40 general practices in
each of the three arms. The patients will visit the general practice at baseline, 3, 6, 9, and 12 months. At each
planned and unplanned visit to the general practice treatment will be adjusted with support of an internet-based
asthma monitoring system supervised by a central coordinating specialist nurse. Patient preferences and utilities
will be assessed by questionnaire and interview. Data on asthma control, treatment step, adherence to treatment,
utilities and costs will be obtained every 3 months and at each unplanned visit. Differences in societal costs
(medication, other (health) care and productivity) will be compared to differences in the number of limited activity
days and in quality adjusted life years (Dutch EQ5D, SF6D, e-TTO, VAS). This is the first study to assess patient
preferences and cost-effectiveness of asthma treatment strategies driven by different target levels of asthma
control.
Trial registration: Netherlands Trial Register (NTR): NTR1756
Background
Despite the availability of effective therapies, asthma
remains a source of significant morbidity and use of
health care resources [1,2]. The societal costs of asthma
are considerable. Asthma negatively affects work produc-
tivity as well as labour force participation. Furthermore, a
survey showed that in the Netherlands 30% of asthmatics
needed urgent care in the past year, which was on aver-
age 8% more than in other European countries [3].
Under a system designed for acute rather than chronic
care, patients are not adequately taught to care for their
own illness. Sixty-two percent of patients visit their pul-
monary specialists or general practitioners only if they
have an acute health problem. Only 15% of Dutch asth-
matics had a doctor-written action plan for their asthma
[3]. In addition, there is a major discrepancy between
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severity [4]. National and international guidelines define
the goal of treatment as to achieve and maintain clinical
asthma control [5,6]. Daily treatment with inhaled corti-
costeroids is recommended on a long-term basis as first-
line therapy to keep asthma under clinical control in
patients with persistent asthma. Short-term bronchodila-
tors are used on an as-needed basis to reverse broncho-
constriction and relieve symptoms. The 2006 updated
international guidelines [6] introduced a management
approach based on asthma control. According to the
Global Initiative for Asthma (GINA) guidelines the levels
of asthma control are defined as follows:
1) Partly controlled asthma is defined as the presence
of any of the following: daytime symptoms ≥ twice per
week, limitations of activities, nocturnal symptoms, need
for reliever treatment, reduced lung function and
exacerbations (further referred as sufficiently controlled).
2) Controlled asthma is defined as daytime symptoms
that are present ≤ twice per week or the absence of lim-
itations of activities, nocturnal symptoms, need for relie-
ver treatment, reduced lung function and exacerbations
(further referred as strictly controlled).
3) Uncontrolled asthma is defined as ≥ 3 features of
partly controlled or the presence of an exacerbation.
The level of asthma control can be assessed using com-
posite measures such as the validated Asthma Control
Questionnaire (ACQ) [7]. Each patient should be
assessed to establish the current treatment regimen,
adherence to the current regimen, and the level of
asthma control. If asthma is uncontrolled on the current
treatment regimen, treatment should be stepped up until
control is achieved. If asthma is partly controlled, the
guidelines recommend that a step-up in treatment should
be considered.
Strictly controlled asthma can be achieved in the
majority of patients with uncontrolled asthma by a treat-
ment strategy with (high dose) inhaled corticosteroids
alone or with combination therapy of an inhaled corti-
costeroid and a long-acting bronchodilator [8]. Symp-
toms and lung function will improve and the number of
awakenings and severe exacerbation rate will reduce [9].
However, this is in marked contrast with the levels of
control observed in community studies, where patients
tend to be partly controlled [4]. Current guidelines show
some ambiguity whether treatment target should be con-
trolled or partly controlled [6]. Another question is not
only whether maximal doses of (combination) therapy
should be used for long periods in an attempt to achieve
complete control of all features of asthma, but also
whether patients would value the potential incremental
benefit sufficiently to concur with such a treatment
approach [10]. In addition, there is only limited data
available on the cost-effectiveness of treatment strategies
aimed at different levels of asthma control [11,12].
Recently, the fraction of exhaled nitric oxide (FeNO)
has been introduced as a non-invasive marker of airway
inflammation in asthma. The role of FeNO in titrating
anti-inflammatory treatment to the most effective dose
of inhaled corticosteroids in asthma is still controversial
[13]. Addition of FeNO as an indicator of control of
asthma has led to higher [14] as well as lower [15] doses
of inhaled corticosteroids without a difference in symp-
tomatic asthma control. Adjustments to medication
dose based on FeNO measurements seem to reduce the
number of exacerbations, but recent studies had insuffi-
cient power to reach statistical significance when adjust-
ing for multiple exacerbations within patients [16].
Therefore, it is not yet determined whether FeNO mea-
surements may indicate whether a step-up in treatment
is effective or a step-down can be achieved without loss
of asthma control and thereby contribute to the effi-
ciency of asthma care.
Therefore, we aim to investigate whether a treatment
strategy aimed at strict asthma control is more (cost-)
effective as compared to a treatment strategy aimed at
achieving sufficiently controlled asthma. In addition we
postulate that a treatment strategy aimed at strict
asthma control is more (cost-)effective when the treat-
ment step is additionally guided by measurements of
exhaled nitric oxide (FeNO) as compared to a treatment
strategy aimed at achieving strictly controlled asthma or
sufficiently controlled asthma without the addition of
FeNO.
Preliminary results
Monitoring control
An internet application will be used to assist the physician/
nurse practitioner/physician assistant in adjusting the treat-
ment step according to the 3 treatment algorithms. In the
Self-Management of Asthma Supported by Hospitals,
Information and communication technology, Nurses and
General practitioners (SMASHING) -project we have
already used an internet application for monitoring Forced
Expiratory Volume in 1 second (FEV1) and asthma control
questionnaire (ACQ) [17]. Furthermore, in this project we
have set-up electronic versions http://www.netquestion-
naires.nl of the majority of questionnaires. In the OPPAS-
project (UMCN) we have already explored the distribution
of levels of asthma control in general practice patients with
asthma [18].
Design
The study is a cluster-randomised parallel trial with 3
arms and 12 months follow-up (Figure 1). In order to
avoid recruitment bias the identification of potential
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Page 2 of 11patients from the general practice information system
will be performed before the allocation of a general
practice cluster to a treatment strategy [19,20]. The 3
treatment strategies are defined as:
1 SUFF-strategy: achieving sufficiently controlled
asthma based on conventional asthma control measures
2 STRICT-strategy: achieving strictly controlled
asthma based on conventional asthma control measures
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Figure 1 Flowchart of the ACCURATE trial.
Honkoop et al. BMC Pulmonary Medicine 2011, 11:53
http://www.biomedcentral.com/1471-2466/11/53
Page 3 of 113 FeNO-strategy: achieving strictly controlled asthma
based on conventional asthma control measures and an
indirect marker of airways inflammation (FeNO).
General practices will be randomly assigned to the 3
groups using a computer generated permuted block
scheme, ensuring concealment of allocation. Treatment
assignment will be stratified according to characteristics of
general practices (solo/duo/etc practice, rural/urban). The
patients will visit the general practice for an introduction
visit and control visits at baseline, 3, 6, 9, and 12 months.
In case of asthma exacerbations patients pay an additional
visit to the general practice or chest physician.
Intervention
The level of asthma control will be based on a 3-monthly
assessment of asthma symptoms, number and severity of
exacerbations, FEV1, with or without the level of FeNO.
Asthma symptoms will be assessed with the ACQ, which
is closely associated with the level of asthma control from
the GINA guidelines (Table 1). Step-ups in medication
will be adjusted (Table 2), using specific algorithms for the
3 treatment strategies (Table 3). The step-up in medica-
tion in the FeNO-strategy will be additionally guided by
the level and change in FeNO according to recent recom-
mendations and the latest available evidence [21]. This
allows adjustment of the dosage of inhaled corticosteroids
based on information of airways inflammation whilst the
dosage of additional reliever medication is based on
asthma control measures [21]. At each planned and
unplanned visit during the 12 months follow-up mainte-
nance, therapy will be adjusted according to the relevant
algorithm, using the internet-based asthma monitoring
system by either the nurse practitioner or general practi-
tioner [17]. This allows the supervision of this process by a
central coordinating nurse specialist.
Patients
720 Patients with mild to moderate persistent asthma
(prevalent cases) will be recruited from general practices
via patient registries in three regions in The Netherlands:
- Leiden University Medical Center (LUMC) general
practice network LEON (240 patients, 40 general
practices)
- Radboud University Nijmegen Medical Centre gen-
eral practice network (240 patients, 40 general practices)
- Amsterdam Medical Center (AMC) general practice
network (240 patients, 40 general practices)
Only general practices with a practice nurse (or nurse
practitioner/or physician assistant, further referred to as
‘practice nurse’) will participate (70% of general practices
in the Netherlands currently have a employed such a pro-
fessional [22]). Based on previous research experience in
patients with asthma in general practice (SMASHING-
project CME number P05.136), we estimate a response
rate of 40% with an inclusion of 6 patients per ‘standard’
practice (i.e. practice with 2,300 patients) and 40 ‘standard’
general practices per treatment strategy.
Inclusion criteria (all of the following criteria)
- age 18-50 yr
- doctor’s diagnosis of asthma
- patients who need inhaled corticosteroids as control-
ler medication (step 2-4 GINA guidelines)
- inhaled corticosteroids ≥ 3 months in the previous
year
- written informed consent
- no exacerbation of asthma within 1 month before
entry
Exclusion criteria - daily or alternate day oral corticos-
teroid therapy for at least 1 month before entering into
the study
- inability to understand written and oral Dutch
instructions
- active diseases likely to interfere with the purpose of
the study, such as end-stage disease or inability to visit
the general practitioner
Methods of measurements
At baseline, patient characteristics will be assessed includ-
ing questions on atopy, smoking and symptom free days.
Table 1 Levels of Asthma Control
Characteristic Strictly Controlled (All of
the following)
Sufficiently Controlled (Any measure
present in any week)
Uncontrolled
Daytime symptoms None (twice or less/week) More than twice/week Three or more features of sufficiently controlled
asthma present in any week
Limitations of activities None Any
Nocturnal symptoms/
awakening
None Any
Need for reliever/
rescue treatment
None (twice or less/week) More than twice/week
Lung function (FEV1) Normal < 80% predicted
Exacerbations* None 1
st moderate exacerbation ≥ 2 moderate exacerbation
† or severe
exacerbation
*modified from the GINA guidelines; the presence of an exacerbation influences the level of asthma control at baseline or at an exacerbation. If one or more
exacerbations have led to an adjustment in treatment, this category starts at 0 again. At baseline: treatment levels only will be adjusted when exacerbations
were present ≤ 3 months prior to the study: † during the same treatment regime.
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titioners [3], patients are invited to visit their general prac-
tice every 3 months in order to titrate medication to the
lowest level that is needed to achieve or maintain control.
3-Monthly care by the nurse practitioner will be organized
similar to the advise in the national guidelines for general
practitioners [5], including questions on asthma control,
medication, adverse events and measurement of lung
function. At all planned and unplanned visits question-
naires will be performed at home (Table 4). In addition,
the ACQ will be performed at home monthly as an out-
come measure. Peripheral blood will be obtained at base-
line. Both paper and electronic versions will be used to
collect the data, depending on the preference of a patient.
Electronic versions in the ACCURATE project will be
similar to those from the SMASHING project http://www.
netquestionnaires.nl. A coordinating nurse specialist will
supervise the nurse practitioners.
Assessment of level of asthma control At each planned
and unplanned visit to the general practice a nurse prac-
titioner will assess the level of asthma control with:
1. asthma control questionnaire (ACQ-score) [7]
2. lung function level (FEV1)
3. FeNO (only in the FeNO-strategy)
4. presence of exacerbations, now or in previous weeks
Asthma control questions Asthma control will be
assessed every 3 months with the Asthma Control Ques-
tionnaire (ACQ), which consists of 6 items with a 7-point
scale (0 = totally controlled, 6 = severely uncontrolled)
[7]. In addition, the ACQ will be completed monthly at
home. The ACQ contains questions on respiratory symp-
toms over the previous week. The patients will be asked
whether these symptoms were representative for the last
4 weeks. If not, the ACQ will be assessed from the most
representative of the last 4 weeks. The optimal cut-point
for “strictly controlled” asthma is defined as a mean ACQ
score ≤ 0.75 and a score of ≥1.50 confirms “uncontrolled”
asthma [23]. We regard control to be sufficient if 0.75 <
mean ACQ < 1.50.
Lung function measurements Spirometry will be per-
formed in the general practices according to national [5]
and international guidelines [24]. For the baseline visit
Table 3 Treatment strategy algorithms
Levels of asthma control
Strategy Strictly controlled Sufficiently controlled Uncontrolled
STRICT-strategy - 3 mo: no change step-up: treatment choice step-up: treatment
choice
- > 3 mo: step-down
SUFF-strategy step-down no change step-up: treatment
choice
FeNO strategy
- Low FeNO level step-down - 3 mo: no change/change within current step to
LABA
step-up: LABA
- > 3 mo: step-down ICS
- Intermediate FeNO
level
no change step-up: treatment choice step-up: treatment
choice
- High FeNO level step-up/change within current step to
ICS
step-up: 1 × ICS step-up: 2 × ICS*
STRICT-strategy = strictly controlled strategy; SUFF-strategy = sufficiently controlled strategy. A raised FeNO level is indicative of eosinophilic airway inflammation;
ICS = inhaled corticosteroids; LABA = long-acting ß2-agonist. *until a maximum high dose of ICS is reached
Table 2 Management approach based on control (GINA guidelines)
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5
Asthma education
Environmental control
As needed rapid-acting
ß2-agonist
As needed rapid-acting ß2-agonist
Select one Select one Add one or more Add one or both
Low-dose ICS* Low-dose ICS plus long-acting
ß2-agonist
Medium- or high dose ICS plus long-
acting ß2-agonist
Oral corticosteroid
(lowest dose)
Leukotriene
modifier
Medium- or high dose ICS Leukotriene modifier Anti-IgE treatment
Low-dose ICS plus Leukotriene
modifier
†
*ICS = inhaled corticosteroids
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Page 5 of 11Table 4 Instrument Table
Assessment of level of asthma
control:
Outcomes
driving treatment step
Patient preferences Quality of life Patient utilities Costs
airway
inflammation
lung
function
asthma
control
beliefs about
medicines
adherence adherence patient
statisfaction
generic asthma
related
patient
perspective
asthma
related
societal
perspective
health care +
other costs
FeNO FEV1 ACQ IPQ MARS BMQ FACCT SF-36 AQLQ TTO ASUI EQ-5D CostQ
Baseline XX X X X X XX X X X X X
Unplanned
visit
FX X XX X
3 months FX X XX X X
6 months FX X X X X X X X X X X X
9 months FX X XX X X
12 months XX X X X X XX X X X X X
X in all treatment strategies, F only in FeNO strategy
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1patients will be instructed to refrain from bronchodila-
t o ru s ef o ras p e c i f i e dn u m b e ro fh o u r sb e f o r et h e
scheduled spirometry test. Reversibility of airways
obstruction will be measured 20 min after administering
4 single puffs of 100 μg salbutamol per metered dose-
inhaler connected to a spacer (Volumatic
®). The
response will be expressed as ml and percentage change
in predicted value of FEV1.
Exhaled nitric oxide Fraction of exhaled Nitric Oxide
(FeNO) will be measured in the general practices accord-
ing to international guidelines [25] with the NIOX-MINO
( A e r o c r i n e ,S o l n a ,S w e d e n )[ 2 6 ] .A tb a s e l i n ea n da tt h e
last visit all patients will perform FeNO measurement,
whereas at 3, 6, and 9 months FeNO only will be assessed
in the FeNO Group. FeNO will be measured before spiro-
metric manoeuvres, at an exhaled rate of 50 ml/sec main-
tained for 10 seconds. Patients are not allowed to smoke
at least one hour before the measurements. Results are
expressed as the NO concentration in ppb (equivalent to
nanolitres/litre) based on the first approved measurement.
FeNO levels will be categorized into low when FeNO ≤
25 ppb (absence of inflammation), intermediate 25 ppb <
FeNO < 50 ppb and high FeNO ≥ 50 ppb (presence of
airway inflammation) [13]. Results will be adjusted for
smoking (yes/no), gender and height [27].
Exacerbations Patients will be instructed to pay an addi-
tional visit to their general practice if they experience
worsening of asthma symptoms. In line with the national
[5] and GINA guidelines [6] exacerbations of asthma are
defined as acute or subacute episodes of progressively
worsening shortness of breath, cough, wheezing, and
chest tightness, or some combination of these symptoms
[28] and will be treated by the general practitioner [5].
FeNO will be performed only in the FeNO strategy.
Additional questionnaires and lung function will be per-
formed at home (Table 4).
After an exacerbation is resolved the patient visits the
nurse practitioner who will assess the current level of
asthma control. GINA is not clear about the incorporation
of exacerbations in the assessment of asthma control
(Table 4.3-1 from the GINA guidelines; ‘personal commu-
nication’), but in the same GINA document exacerbations
are also referred to as evidence of poor asthma control.
Therefore, in the present study exacerbations are handled
as follows. Questions will be asked on new respiratory
symptoms, medication change and hospitalisation [28].
The exacerbation will be classified according to severity as
based on the presence of respiratory symptoms, prescribed
medication and/or hospitalisation. A moderate exacerba-
tion is defined as a (sub)acute deterioration in symptoms
and/or lung function with increased rescue bronchodilator
use (or ICS) which lasts 2 days or more, not severe enough
warrant oral steroids (for 3 days or more) or hospitalisa-
tion. A severe exacerbation is defined as (sub)acute
deterioration in asthma resulting in the need for oral ster-
oids for 3 days or more or hospitalisation (as judged by
the physician) [29]. Subsequently, the level of control will
be assessed as based on Table 1 and maintenance therapy
will be assigned according to the treatment algorithm after
exacerbation treatment is finished.
Assessment of cost-utilities and patient preferences
Costs - cost questionnaires: health care consumption;
absenteeism and productivity loss (CostQ) [30]
Patient preferences - the Foundation for Accountability
(FACCT) [31]
- the Brief Illness Perception Questionnaire (Brief
IPQ) [32]
- the Beliefs about Medicines Questionnaire (BMQ)
[33]
- Medication Adherence Report Scale (MARS) [34,35]
Quality of life, patient utilities - quality of life: Asthma
Quality of Life Questionnaire (AQLQ) [36] and Short-
Form 36 (SF-36) [37]
- patient utilities: the Asthma Symptom Utility Index
(ASUI) [38]. Patient utilities will additionally be assessed
by the time-trade-off method by telephonic interview
a n daw e b - p a g e( e - T T O )a te a c hp l a n n e da n d
unplanned period (exacerbation) [39]
- indirect utilities from the general public will be
obtained using the SF-6D [37,34] and EQ-5D [40,41]. This
allows the calculation of quality adjusted life years
(QALYs).
- number of limited activity days by questionnaire
Analysis
The analysis will be carried out on an intention to treat
basis. The data set will consist of all included patients
from randomised practices.
Sample-size calculation A minimally important change
in patient utility (EQ-5D) has been defined as 0.074 point
[42]. With 150 patients per treatment strategy we are
able to detect at least a change of 0.06 points by net
health benefit analysis [43] between the arms with a SD
= 0.175 EQ-5D points (baseline data SMASHING-project;
trial registry number NTR826: SD = 0.17) and a SD of
€1000 for costs (SD = €816, usual care strategy [44]) and
an increase in costs of €250 when a treatment strategy is
not only more effective but also more costly, for a will-
ingness-to-pay (WTP) of €30K (alpha = 0.05, one sided
[43], beta = 0.20, one sided, rho costs-effects = 0) (Figure
2). With 40 clusters (general practices) per arm and
assuming an intra-cluster correlation of 0.01, 0.07 and
0.11 the number of patients per cluster is 4, 5, and 6, and
the total number of patients is 480, 600 and 720, respec-
tively [45].
Data-analysis and presentation/synthesis At baseline,
data from all planned and unplanned contact will be
collected according to the scheme in Table 4. The
instruments include variables of:
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tus, smoking status and smoking history
- medical outcomes:F E V 1, FeNO, ACQ, current treat-
ment step, asthma medication
- patient preferences: FACCT, IPQ, BMQ, MARS
- quality of life: AQLQ, SF-36
- patient utilities: ASUI, SF-6D and EQ-5D, QALYs, e-
TTO, number of limited activity days
- costs: health care consumption; CostQ
Economic evaluation
General considerations The economic evaluation will
compare differences in societal effects and costs to dif-
ferences in the number of limited activity days (cost-
effectiveness analysis, CEA) and quality adjusted life
years (cost-utility analysis, CUA). The analysis will have
a 12-months time horizon, without discounting. Group
averages will be statistically compared using two-sided
bootstrapping and net-benefit analysis will be used to
relate costs to patient outcome. Sensitivity analyses will
be performed on the perspective (societal versus health
care) and the applied utility measure (Dutch EQ5D,
SF6D, e-TTO, AQLQ-5D).
Cost-effectiveness The primary end-point is the evalua-
tion of the cost-effectiveness of treatment strategies by
incremental net-benefit analysis [43]. Net health benefit
addresses cost-effectivene s sr a t i o sb ya s s u m i n gv a l u e s
for the willingness-to-pay per unit of effectiveness.
Cost analysis The cost analysis will include both medi-
cal (medication, visits, and hospitalizations) and non-
medical costs (productivity losses, informal care). Pur-
chased medication will be assessed from electronic
patient records (with written patient permission), com-
plemented with the patient’s report on medication pur-
chased elsewhere [46]. Other costs will be estimated
using quarterly cost questionnaires (CostQ) [30]. Costs
will be valued according to standard prices charges [47]
including time and travel costs.
Analysis of effectiveness The differences in levels and
changes in utilities based on EQ-5D, SF-6D, VAS, e-
TTO and the number of limited activity days will be
Figure 2 Power curve of the required sample-size per treatment arm. The curve is represented as a function of willingness-to-pay (WTP) for
a range of increases in costs (delta Costs) when a treatment strategy is not only more effective but also more costly. The presented +sample-size
is unadjusted for intra-cluster correlation. A minimally important change in patient utility (EQ-5D) has been defined as 0.074 point. With 150
patients per treatment strategy we are able to detect at least a change of 0.06 points by net health benefit analysis between the arms with a SD
= 0.175 EQ-5D points (baseline data SMASHING-project: SD = 0.17) and a SD of €1000 for costs (SD = €816, usual care strategy) and an increase
in costs of €250 (delta Costs) when a treatment strategy is not only more effective but also more costly, for a willingness-to-pay (WTP) of €30K
(alpha = 0.05, one-sided, beta = 0.20, one-sided, rho costs-effects = 0). With 40 clusters (general practices) per arm and assuming an intra-cluster
correlation of 0.01, 0.07 and 0.11 the number of patients per cluster is 4, 5, and 6, and the total number of patients is 480, 600 and 720,
respectively.
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Page 8 of 11compared between the treatment strategies using a ran-
dom-effects analysis accounting for within-patient
repeated measurements and clustering on general
practice.
Patient outcome analysis Utilities will be assessed
every three months. In the base case analysis, quality-
adjusted life years (QALYs) will be estimated using soci-
etal utilities obtained using the Dutch EQ5D tariff [48].
As sensitivity analyses, QALYs will be estimated using
the SF-6D and individual utilities obtained using the e-
TTO and visual analogue scale (transformed using a
power transformation).
Ethical approval
Ethical approval was obtained from the Medical Ethics
Committee of the Leiden University Medical Center
(ABR no: 24488).
Discussion
The aim of the ACCURATE trial is to compare the cost-
effectiveness and patient preferences of three asthma treat-
ment strategies: 1) sufficiently controlled strategy, aiming
to achieve sufficiently controlled asthma based on conven-
tional asthma control measures (ACQ and lung function);
2) strictly controlled strategy, aiming to achieve controlled
asthma also based on asthma conventional control mea-
sures; and 3) FeNO-strategy, aimed at achieving strictly
controlled asthma based on conventional asthma control
measures plus an indirect marker of airways inflammation.
For this purpose we will implement an internet-based pro-
gramme, to be used by care providers in general practices.
To our knowledge, this is the first study to assess patient
preferences and cost-effectiveness of asthma treatment
strategies aimed at different levels of control on asthma.
Notably, the current study is fully investigator driven,
granted by governmental funding rather than pharmaceu-
tical funding. Current guidelines advise clinicians to
ensure that asthma is strictly controlled, i.e. patients
should not experience any symptoms. However, in daily
practice, a considerable proportion of asthma patients
continuously experience symptoms without consulting
their physician [49]. This raises the question of patient’s
preferences with regard to treatment aims. It is not yet
known whether patients are willing to conform to the
stringent treatment aim of strictly controlled asthma, espe-
cially if it results in high doses of asthma medication and
an increased likelihood of concurrent side effects. These
uncertainties hamper implementation of current guide-
lines and therefore a great diversity in treatment exists.
Furthermore, discordance in patient’s and medical treat-
ment goals might result in unnecessary asthma symptoms
and health care use.
A recent meta-analysis showed that FeNO guided treat-
ment of asthma does not reduce the number of exacerba-
tions; however it did reduce the daily dose of inhaled
corticosteroids [50]. Our study may extend these findings
by providing further understanding of the cost-effective-
ness and patient preferences of FeNO guided treatment of
asthma.
We hypothesize that:
1) a treatment strategy aimed achieving at strictly con-
trolled asthma is more (cost-)effective as compared to a
treatment strategy aimed at sufficiently controlled
asthma;
2) a treatment strategy aimed at achieving strictly con-
trolled asthma is (cost-)effective when the treatment
step is additionally guided by measurements of exhaled
nitric oxide (NO) as compared to a treatment strategy
aimed at strictly controlled asthma or sufficiently con-
trolled asthma.
During the conduction of the trial the definition of
asthma exacerbations has been changed. In our analysis
we will use the definitions as proposed by the ATS/ERS
task force [51]. By incorporating internet-based graphic
feedback on a patients’ asthma control status and inter-
net-based decision support based on current guidelines,
we will enhance the feasibility and standardization of
the treatment advice. The results of this study will pro-
vide insight into the potential discordance between
patient’s and medical treatment goals and the effect on
health care costs from the societal perspective. The
internet-based decision support methodology and results
of our study may facilitate cost-effective implementation
of future tailored treatment strategies for patients with
mild to moderate asthma in primary care.
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